MX2009009200A - Tratamiento de enfermedades caracterizadas por la inflamacion. - Google Patents

Tratamiento de enfermedades caracterizadas por la inflamacion.

Info

Publication number
MX2009009200A
MX2009009200A MX2009009200A MX2009009200A MX2009009200A MX 2009009200 A MX2009009200 A MX 2009009200A MX 2009009200 A MX2009009200 A MX 2009009200A MX 2009009200 A MX2009009200 A MX 2009009200A MX 2009009200 A MX2009009200 A MX 2009009200A
Authority
MX
Mexico
Prior art keywords
treatment
inflammation
diseases characterized
methods
pathway
Prior art date
Application number
MX2009009200A
Other languages
English (en)
Inventor
Michael Kaleko
Tianci Luo
Original Assignee
Advanced Vision Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Vision Therapies Inc filed Critical Advanced Vision Therapies Inc
Publication of MX2009009200A publication Critical patent/MX2009009200A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La invención proporciona, en parte, métodos, ácidos nucleicos, vectores, proteínas y moléculas de enlace que se pueden utilizar para modular una vía tal como una vía del complemento. Estos métodos y composiciones se pueden utilizar, inter alia, para el estudio y/o tratamiento de varias condiciones o enfermedades relacionadas con una vía del complemento.
MX2009009200A 2007-03-01 2008-02-29 Tratamiento de enfermedades caracterizadas por la inflamacion. MX2009009200A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89239507P 2007-03-01 2007-03-01
US98502407P 2007-11-02 2007-11-02
PCT/US2008/055498 WO2008106644A2 (en) 2007-03-01 2008-02-29 Treatment of diseases characterized by inflammation

Publications (1)

Publication Number Publication Date
MX2009009200A true MX2009009200A (es) 2009-10-28

Family

ID=39721854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009200A MX2009009200A (es) 2007-03-01 2008-02-29 Tratamiento de enfermedades caracterizadas por la inflamacion.

Country Status (10)

Country Link
US (1) US20100120665A1 (es)
EP (1) EP2134173A4 (es)
JP (1) JP5332064B2 (es)
KR (1) KR20090122465A (es)
AU (2) AU2008221287A1 (es)
CA (1) CA2678774A1 (es)
IL (1) IL200368A0 (es)
MX (1) MX2009009200A (es)
NZ (1) NZ578873A (es)
WO (1) WO2008106644A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704973A1 (en) * 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor b antibodies and their uses
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
EP2252317B1 (en) * 2008-02-15 2014-04-09 Tufts University Treatment of macular degeneration
WO2012016162A2 (en) * 2010-07-29 2012-02-02 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
ES2762864T3 (es) 2008-06-18 2020-05-26 Oxford Biomedica Ltd Purificación de virus
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US11512326B2 (en) 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
FR2952639B1 (fr) * 2009-11-16 2013-08-30 Lab Francais Du Fractionnement Procede de purification de facteur b
JP5337096B2 (ja) 2010-04-28 2013-11-06 株式会社日立製作所 動脈硬化の評価法
WO2012021891A2 (en) * 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of complement-related disorders
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
SG194780A1 (en) 2011-05-05 2013-12-30 Wellstat Immunotherapeutics Llc Complement factor b analogs and their uses
CN103796667A (zh) * 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
AU2012321102C1 (en) 2011-10-27 2016-11-10 Pharma Cinq, Llc Vectors encoding rod-derived cone viability factor
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
CN103316356B (zh) * 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
WO2013148155A1 (en) * 2012-03-26 2013-10-03 Digna Biotech Usa, Llc Compositions and methods for the treatment of dry eye disease
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
WO2014035876A1 (en) * 2012-08-27 2014-03-06 William Marsh Rice University Heat-inactivated complement factor b compositions and methods
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN105229003B (zh) 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
DK2986635T3 (en) * 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
EP3633039A1 (en) 2013-05-01 2020-04-08 Ionis Pharmaceuticals, Inc. Compositions and methods
ES2650917T3 (es) 2013-08-07 2018-01-23 Alexion Pharmaceuticals, Inc. Proteínas biomarcadoras del síndrome urémico hemolítico atípico (SUHA)
EP3043827B1 (en) * 2013-09-13 2019-07-03 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
JP2016535042A (ja) 2013-10-30 2016-11-10 ノバルティス アーゲー ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用
EP3107939B1 (en) 2014-02-19 2020-06-17 University of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
AU2015229381B2 (en) * 2014-03-11 2019-11-07 University Of Florida Research Foundation, Inc. Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
PE20170010A1 (es) 2014-05-01 2017-03-04 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion del factor b del complemento
US11666777B2 (en) * 2014-05-12 2023-06-06 Gholam A. Peyman Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
US11518791B2 (en) 2016-05-23 2022-12-06 Luxembourg Institute Of Health (Lih) Multifunctional heteromultimeric constructs
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
IL263979B2 (en) 2017-05-10 2023-09-01 Wellstat Immuno Therapeutics Llc Viruses with an envelope resistant to the immune system for cancer treatment
KR20210092755A (ko) * 2018-11-14 2021-07-26 리젠엑스바이오 인크. 신경원성 세로이드 리포푸신증에 대한 유전자 요법
US11707505B2 (en) * 2019-11-15 2023-07-25 King Faisal Specialist Hospital & Research Centre VCP and factor H as viral entry inhibitors
US20230173024A1 (en) * 2020-04-01 2023-06-08 The Trustees Of The University Of Pennsylvania Factor b inhibitors and uses thereof
WO2023230171A2 (en) * 2022-05-24 2023-11-30 University Of Pittsburgh - Of Thecommonwealth System Of Highereducation Compositions and methods of treating corneal scarring

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5869615A (en) * 1994-01-03 1999-02-09 Washington University Modified complement proteases
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
DK2026073T3 (en) * 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US20060178348A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID
EP1863931A2 (en) * 2005-03-07 2007-12-12 The Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration
CA2626356C (en) * 2005-10-21 2017-08-22 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation

Also Published As

Publication number Publication date
WO2008106644A2 (en) 2008-09-04
CA2678774A1 (en) 2008-09-04
JP5332064B2 (ja) 2013-11-06
KR20090122465A (ko) 2009-11-30
JP2010520224A (ja) 2010-06-10
EP2134173A4 (en) 2010-11-10
EP2134173A2 (en) 2009-12-23
WO2008106644A3 (en) 2008-11-20
AU2008221287A1 (en) 2008-09-04
US20100120665A1 (en) 2010-05-13
IL200368A0 (en) 2010-04-29
NZ578873A (en) 2012-01-12
AU2014203398A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX345226B (es) Formulaciones de moleculas de union a antigeno de dominio sencillo.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MX2019005911A (es) Anticuerpos anti_cd137 novedosos y usos de estos.
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201001883A1 (ru) Мутанты fgf21 и их применение
MX2018000470A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22).
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
TN2010000169A1 (en) Molecules and methods for modulating complement component
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
MX2009004038A (es) Gel de diclofenaco.
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
EP3495485A3 (en) Exon skipping compositions for treating muscular dystrophy
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
UA97536C2 (en) Proteasome inhibitors
EA201490644A1 (ru) Терапевтические пептиды
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
MX2012006206A (es) Preparaciones combinacion comprendiendo exosomas y corticosteroide.
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень

Legal Events

Date Code Title Description
FA Abandonment or withdrawal